Literature DB >> 32468869

Experience of mismatch repair/microsatellite instability (MMR/MSI) testing among patients with advanced/metastatic colorectal cancer in the US.

Jennifer Eriksson1, Mayur Amonkar2, Gemma Al-Jassar3, Jeremy Lambert4, Mia Malmenäs1, Monica Chase2, Lucy Sun5, Linda Kollmar2, Michelle Vichnin2.   

Abstract

Objective: We assessed knowledge and awareness of MMR/MSI testing among advanced/metastatic CRC patients in the US who had previously taken the test.
Methods: A non-interventional, cross-sectional online survey was conducted among 150 US CRC patients invited through a research panel. Eligible patients had to be ≥18 years, with stage III or IV CRC (self-reported), had undergone MMR/MSI testing for CRC in past 12 months and could recall the test, and provided informed consent. Descriptive analyses were performed.
Results: 81.3% of patients received MMR/MSI testing information from their doctor. Of 64.7% of patients who were a member of a patient support group, 86.6% received information from their groups. Most patients (82.7%) also searched for information on their own (internet searches). Most patients (93.5 to 96.9%) were satisfied with information received from these sources. Reasons for having testing done included increasing knowledge about their cancer (69.3%), being beneficial to determining treatment options (60.7%), and doctor recommendation (62.7%). Key barriers to testing included personal reservations regarding benefits of the test (29.3%), insurance coverage (27.3%), and out-of-pocket costs (18.7%); 45.3% reported no barriers.Conclusions: Patients were well informed about MMR/MSI testing. Increased education of testing benefits and addressing financial barriers may help to further improve testing rates.

Entities:  

Keywords:  Colorectal cancer; mismatch repair/microsatellite instability testing; patient; survey

Mesh:

Year:  2020        PMID: 32468869     DOI: 10.1080/03007995.2020.1776235

Source DB:  PubMed          Journal:  Curr Med Res Opin        ISSN: 0300-7995            Impact factor:   2.580


  2 in total

1.  Underutilization of Guideline-Recommended Mismatch Repair/Microsatellite Instability Biomarker Testing in Advanced Colorectal Cancer.

Authors:  David J Papke; Neal I Lindeman; Deborah Schrag; J Bryan Iorgulescu
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2022-09-02       Impact factor: 4.090

Review 2.  Evolution of predictive and prognostic biomarkers in the treatment of advanced gastric cancer.

Authors:  Nicole M Myer; Kohei Shitara; Hyun C Chung; Florian Lordick; Ronan J Kelly; Zsolt Szabo; Z Alexander Cao; Stephen Leong; David H Ilson; Wilko Weichert
Journal:  J Cancer Res Clin Oncol       Date:  2022-05-13       Impact factor: 4.322

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.